Filter documents Clear search

pdf icon

FSRH CEU response public consult desogestrel POP as pharmacy medicine - Feb 2021

File size: 380kb | Date: 18 February 2021 | FSRH Response - PDF

This statement is a FSRH CEU response to a public consultation conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding licensing of two brands of desogestrel 75mcg progestogen-only pill (POP) as Pharmacy Medicines (P). The products are Hana® (Laboratoire HRA Pharma) and Lovima® (Maxwellia Ltd).

pdf icon

FSRH statement: MHRA changes its regulatory position on sodium valproate

File size: 98kb | Date: 24 April 2018 | FSRH Response - PDF

On 24 April the Medicines and Healthcare Products Regulatory Agency (MHRA) changed its regulatory position on medicines containing sodium valproate. MHRA advises that if a woman of childbearing age is to be prescribed sodium valproate, she must be enrolled in a pregnancy prevention programme (PPP). This FSRH statement outlines the implications for daily practice.